Market Overview

Glancy Prongay & Murray LLP Announces Extended Lead Plaintiff Deadline in Securities Class Action on Behalf of Prothena Corporation plc Investors (PRTA)

Share:

National securities litigation law firm Glancy
Prongay & Murray LLP
("GPM") announces that a class action
lawsuit has been filed on behalf of investors that purchased or
otherwise acquired the securities of Prothena Corporation plc
("Prothena" or the "Company") (NASDAQ: PRTA)
securities between October 15, 2015 and April 20, 2018, inclusive
(the "Class Period"). Prothena investors now have until September
17, 2018
to file a lead plaintiff motion.

If you are a shareholder who suffered a loss, click here
to participate.

Investors that suffered losses on their Prothena investments are
encouraged to contact Lesley Portnoy of GPM to discuss their legal
rights in this class action at 310-201-9150 or by email to shareholders@glancylaw.com.

On October 15, 2015, Prothena disclosed its late-stage Phase 2b "PRONTO"
study and expansion of its Phase 1/2 clinical trial for the antibody
NEOD001. On April 23, 2018, Prothena announced it was ending development
of NEOD001 after its Phase 2b PRONTO trial failed to reach either its
primary or secondary endpoints. On this news, shares of Prothena fell
$25.34, or nearly 69%, to close at $11.50 on April 23, 2018, thereby
injuring investors.

The complaint filed in this class action alleges that, Defendants during
the Class Period violated the federal securities laws by: (1)
withholding relevant trial data showing that Prothena's NEOD001, an
antibody designed to treat amyloid light chain amyloidosis ("AL
amyloidosis"), was not an effective treatment for AL amyloidosis; (2)
making misleading comparisons of NEOD001's "best response" rates against
certain prior studies; and (3) touting that Prothena's ongoing Phase 1/2
study of NEOD001 provided a strong basis for late-stage Phase 2b and
Phase 3 studies of NEOD001, even though the full Phase 1/2 study data
demonstrated that NEOD001 was not an effective treatment for AL
amyloidosis.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased shares of Prothena during the Class Period you may move
the Court no later than September 17, 2018 to ask the Court
to appoint you as lead plaintiff. To be a member of the Class you need
not take any action at this time; you may retain counsel of your choice
or take no action and remain an absent member of the Class. If you wish
to learn more about this action, or if you have any questions concerning
this announcement or your rights or interests with respect to these
matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century
Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150,
Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com,
or visit our website at www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

View Comments and Join the Discussion!